See more : PT Bank JTrust Indonesia Tbk (BCIC.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Mydecine Innovations Group Inc. (MYCOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mydecine Innovations Group Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ClickStream Corporation (CLIS) Income Statement Analysis – Financial Results
- DyDo Group Holdings, Inc. (2590.T) Income Statement Analysis – Financial Results
- WisdomTree Battery Metals ETC (AMPS.L) Income Statement Analysis – Financial Results
- AI TRANSPORTATION ACQUISITION CORP Ordinary shares (AITR) Income Statement Analysis – Financial Results
- Grapefruit USA, Inc. (GPFT) Income Statement Analysis – Financial Results
Mydecine Innovations Group Inc. (MYCOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.mydecine.com
About Mydecine Innovations Group Inc.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.49K | 58.49K | 125.57K | 207.66K | 0.00 | 0.00 | 84.00K | 84.00K | 49.00K | 0.00 |
| Cost of Revenue | 9.88K | 128.86K | 0.00 | 37.37K | 94.05K | 109.82K | 246.58K | 1.77M | 1.97M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.88K | -128.86K | 7.49K | 21.12K | 31.52K | 97.83K | -246.58K | -1.77M | -1.88M | 84.00K | 49.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 36.11% | 25.10% | 47.11% | 0.00% | 0.00% | -2,243.43% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.08M | 3.59M | 3.96M | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.15M | 9.98M | 14.74M | 7.74M | 3.27M | 4.88M | 14.62M | 3.92M | 3.64M | 808.13K | 46.40K | 0.00 |
| Selling & Marketing | 1.15M | 0.00 | 0.00 | 2.33M | 71.51K | 730.22K | 693.83K | 259.75K | 41.10K | 14.00K | 0.00 | 0.00 |
| SG&A | 8.30M | 9.98M | 14.74M | 10.07M | 3.34M | 5.61M | 15.31M | 4.18M | 3.68M | 822.13K | 46.40K | 12.97 |
| Other Expenses | 0.00 | 2.82M | 3.99M | 292.02K | 149.99K | -4.54M | -97.92K | -4.28K | -2.95K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.64M | 16.39M | 22.69M | 11.65M | 3.49M | 5.90M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Cost & Expenses | 19.64M | 16.39M | 22.69M | 11.69M | 3.58M | 6.01M | 15.70M | 4.19M | 3.81M | 929.46K | 73.26K | 41.06 |
| Interest Income | 0.00 | 911.59 | 205.27 | 24.67 | 0.00 | 18.62K | 0.00 | 0.00 | 75.00 | 7.00 | 102.00 | 44.97 |
| Interest Expense | 1.30M | 911.59K | 205.27K | 182.87K | 68.31K | 69.95K | 6.90K | 47.42K | 107.13K | 30.02K | 32.88K | 0.00 |
| Depreciation & Amortization | 9.88K | 128.86K | 235.18K | 57.08K | 46.39K | 21.76K | 246.58K | 9.00K | 24.56K | 25.05K | 25.70K | 26.58 |
| EBITDA | -9.38M | -15.92M | -23.14M | -11.12M | -3.21M | -5.78M | -15.46M | -4.18M | -3.83M | -1.17M | 1.44K | -14.21 |
| EBITDA Ratio | 0.00% | 0.00% | -304,709.21% | -19,007.40% | -2,555.37% | -2,782.25% | 0.00% | 0.00% | -4,582.18% | -976.67% | 3.14% | 0.00% |
| Operating Income | -9.39M | -16.05M | -23.07M | -11.21M | -3.32M | -5.80M | -15.70M | 4.19M | 3.72M | 1.11M | 24.16K | -40.80 |
| Operating Income Ratio | 0.00% | 0.00% | -307,847.83% | -19,161.62% | -2,642.24% | -2,792.73% | 0.00% | 0.00% | 4,430.54% | 1,320.65% | 49.31% | 0.00% |
| Total Other Income/Expenses | -11.55M | -1.40M | -515.87K | -15.67M | -18.04M | -7.55M | -1.99M | -3.79M | -264.53K | -464.40K | -83.34K | -45.24 |
| Income Before Tax | -20.95M | -17.24M | -23.58M | -26.95M | -3.51M | -13.36M | -17.56M | -7.96M | -4.64M | -1.23M | -107.60K | -86.03 |
| Income Before Tax Ratio | 0.00% | 0.00% | -314,732.56% | -46,074.45% | -2,793.41% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| Income Tax Expense | 0.00 | -5.39M | 5.14M | 608.14K | 219.51K | 69.95K | 6.90K | -306.19K | 107.13K | 30.02K | 32.88K | 0.00 |
| Net Income | -20.95M | -11.85M | -28.72M | -27.56M | -3.73M | -13.36M | -17.56M | -7.60M | -4.64M | -1.23M | -107.60K | -86.03 |
| Net Income Ratio | 0.00% | 0.00% | -383,287.92% | -47,114.19% | -2,968.22% | -6,431.45% | 0.00% | 0.00% | -5,524.04% | -1,458.97% | -219.59% | 0.00% |
| EPS | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.45 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| EPS Diluted | -0.68 | -1.37 | -6.13 | -12.12 | -8.37 | -122.07 | -311.15 | -243.37 | -191.20 | -58.15 | -44.08 | 0.00 |
| Weighted Avg Shares Out | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.37K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
| Weighted Avg Shares Out (Dil) | 30.70M | 8.65M | 4.68M | 2.27M | 445.47K | 109.41K | 56.43K | 31.25K | 24.27K | 21.08K | 2.44K | 0.00 |
Mydecine Innovations announces inclusion of molecule with improved heart-safe microdose properties in its family of psilocin analogs
Mydecine Innovations says its exclusive dealer identified as licensed psilocybin and MDMA supplier in Canada
Mydecine Innovations announces appointment of Dr Victoria Hale to the company's board of directors
Mydecine submits pre-IND briefing package to FDA for MYCO-001 smoking cessation clinical trial
Mydecine partners with Combat Stress to treat PTSD in veterans with psilocybin
Mydecine to partner with The Newly Institute to offer psychedelic-assisted psychotherapy to patients under Health Canada's Special Access Program
Mydecine to launch Special Access Support and Supply Program broadening access to psychedelic-assisted psychotherapy for patients
Mydecine caps a new milestone in its AI-powered drug discovery program that will allow it to screen billions of compounds
Mydecine to work with Maya to develop a novel digital therapeutics platform for more personalized patient care
Mydecine Innovations is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics
Source: https://incomestatements.info
Category: Stock Reports